Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2010 2
2011 1
2014 2
2015 2
2016 1
2017 1
2018 2
2021 10
2022 10
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, Vyzhga Y, Marzan K, Grebenkina L, Tirosh I, Imundo L, Jerath R, Kingsbury DJ, Sozeri B, Vora SS, Prahalad S, Zholobova E, Butbul Aviel Y, Chasnyk V, Lerman M, Nanda K, Schmeling H, Tory H, Uziel Y, Viola DO, Posner HB, Kanik KS, Wouters A, Chang C, Zhang R, Lazariciu I, Hsu MA, Suehiro RM, Martini A, Lovell DJ; Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Ruperto N, et al. Lancet. 2021 Nov 27;398(10315):1984-1996. doi: 10.1016/S0140-6736(21)01255-1. Epub 2021 Nov 9. Lancet. 2021. PMID: 34767764 Clinical Trial.
Health Equity Implications of Missing Data Among Youths With Childhood-Onset Systemic Lupus Erythematosus: A Proof-of-Concept Study in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Woo JMP, Simmonds F, Dennos A, Son MBF, Lewandowski LB, Rubinstein TB; CARRA Registry investigators. Woo JMP, et al. Arthritis Care Res (Hoboken). 2023 Nov;75(11):2285-2294. doi: 10.1002/acr.25136. Epub 2023 May 30. Arthritis Care Res (Hoboken). 2023. PMID: 37093036
Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.
Sherman MA, Pak K, Pinal-Fernandez I, Flegel WA, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Arthritis Rheumatol. 2023 Sep;75(9):1668-1677. doi: 10.1002/art.42512. Epub 2023 Jul 19. Arthritis Rheumatol. 2023. PMID: 36996276
Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry.
Ringold S, Dennos AC, Kimura Y, Beukelman T, Shrader P, Phillips TA, Kohlheim M, Schanberg LE, Yeung RSM, Horton DB; Childhood Arthritis and Rheumatology Research Alliance Registry Investigators. Ringold S, et al. Arthritis Care Res (Hoboken). 2023 Apr;75(4):715-723. doi: 10.1002/acr.24994. Epub 2022 Dec 21. Arthritis Care Res (Hoboken). 2023. PMID: 35921198
First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Beukelman T, Tomlinson G, Nigrovic PA, Dennos A, Del Gaizo V, Jelinek M, Riordan ME, Schanberg LE, Mohan S, Pfeifer E, Kimura Y; CARRA FROST Investigators. Beukelman T, et al. Pediatr Rheumatol Online J. 2022 Dec 8;20(1):113. doi: 10.1186/s12969-022-00768-6. Pediatr Rheumatol Online J. 2022. PMID: 36482434 Free PMC article.
41 results